Summary A monoclonal antibody raised against the high molecular weight melanoma antigen was labelled with indium-ill and injected intravenously into 25 patients with malignant melanoma. The results obtained from images at 24 and 96 h post i.v. administration of the antibody were compared with results obtained from computerised tomography studies with regard to detection of previously unrecognised sites of metastatic disease and apparent false positive localisation. Detailed study of the patients' clinical condition and detection rates using the two methods suggest that both methods detect approximately 80% of clinically and pathologically confirmed metastases. Of 62 known metastases, the antibody detected 50 (81%), with 17 false positive results. False negatives were most common in the lung. In eight patients the two methods were considered of equal value, in 10 the monoclonal gave a greater amount of clinically relevant information, and in seven the CT was superior. In three patients clinically significant metastatic lesions were detected by the radiolabelled monoclonal and had not been previously recognised either by CT There are now a large number of antimelanoma murine monoclonal antibodies available. A number of these have been analysed in detail with regard to their sensitivity and specificity in tissue sections, and more recently a number have been used for pilot studies with an appropriate radiolabel to assess their value in in vivo detection of previously unrecognised tumour sites. The two antibodies which to date have been most widely used are antibodies raised against the high molecular weight antigen (240,000) (Buraggi et al., 1985; Siccardi et al., 1986; Cerny et al., 1987; Kirkwood et al., 1988) and the antibody 96.5 which identifies the P27 molecule thought to be transferrin (Lotze et al., 1986) . The reported studies with these two groups of monoclonals differ greatly in the dose of radiolabelled antibody used and in the radiolabel. To date iodine-131, indium-111 and technetium99m have all been used in various combinations. Some workers have reported use of whole antibody while others have claimed greater sensitivity and specificity with Fab or F(ab)2 fragments. A recent review has suggested that overall the anti P97 antibody detects 67% of clinically recognised tumour deposits, and that antibody raised against the high molecular weight antigen recognises 80% of such tumour deposits (Larson, 1987) .
There are now a large number of antimelanoma murine monoclonal antibodies available. A number of these have been analysed in detail with regard to their sensitivity and specificity in tissue sections, and more recently a number have been used for pilot studies with an appropriate radiolabel to assess their value in in vivo detection of previously unrecognised tumour sites. The two antibodies which to date have been most widely used are antibodies raised against the high molecular weight antigen (240,000) (Buraggi et al., 1985; Siccardi et al., 1986; Cerny et al., 1987; Kirkwood et al., 1988) and the antibody 96.5 which identifies the P27 molecule thought to be transferrin (Lotze et al., 1986) . The reported studies with these two groups of monoclonals differ greatly in the dose of radiolabelled antibody used and in the radiolabel. To date iodine-131, indium-111 and technetium99m have all been used in various combinations. Some workers have reported use of whole antibody while others have claimed greater sensitivity and specificity with Fab or F(ab)2 fragments. A recent review has suggested that overall the anti P97 antibody detects 67% of clinically recognised tumour deposits, and that antibody raised against the high molecular weight antigen recognises 80% of such tumour deposits (Larson, 1987) .
None of the publications in the literature to date give an account of a clear comparison of the value of radiolabelled monoclonal imaging by comparison with computerised tomography. In most centres CT scanning is the currently accepted method of staging patients with known or suspected metastatic malignant melanoma. We have therefore set out to investigate the relative value of CT scanning and the use of monoclonal antibody scans in 25 patients with malignant melanoma.
Materials and methods

Antimelanoma antibody
The monoclonal antibody used was XMMME-001, kindly made available to us by Xoma Corporation. cell line secreting this antibody was developed by use of parent myeloma cell line P3-X63-AG8 which was derived from a transplantable plasmacytoma of BALB-C origin.
Cultured human melanoma cells were injected into BALB-C mice, and mouse splenocytes were used for hybridisation. The resultant antibody is an IgG 2a and recognises the high molecular weight antigen. Extensive screening of frozen samples of human tissues using the immunoperoxidase technique indicated that the antibody reacted strongly with frozen sections of the great majority of melanoma samples studied and showed little or no reactivity with the majority of other tumours or normal tissues. In adults reactivity comparable in intensity to that seen in melanoma tissue was observed in vascular endothelium and in some nerve cells, with lesser degrees of reactivity in some liver samples and in hair follicles.
Patients Twenty-five patients with stage 2 or stage 3 malignant melanoma gave informed consent for entering into the study for which local Ethical Committee approval and ARSAC approval was obtained. One patient (case 3) died within 24h of administration of the antibody from causes not thought to be related to antibody administration. The first 16 patients, including this patient excluded, were allocated on a random basis to a 1, 5 or 20 mg protein dose. The material was supplied already covalently coupled to DTPA cyclic anhydride. The conjugate was presented as a sterile apyrogenic solution in 10mM HEPES buffer, 0.15 M sodium chloride (pH 7) at a concentration of 1 mg ml-1. Radiolabelling was carried out by adding 0.2 ml of sodium acetate buffer to 70-90 MBq per 0.2 ml of indium-111 (Amersham International plc). Between 1 and 20ml of conjugate solution were added and the mixture incubated at 4°C for 30min. One millilitre of 20% HSA solution was added and made up to a final volume of 27 ml with sterile saline prior to passage through a 0.22pm filter. The dose was administered by slow intravenous injection over 3-4min.
All glassware used was washed carefully in acid and rinsed in distilled demineralised water before use and all solutions were freshly prepared.
When the images of the first 16 patients were analysed it was apparent that good imaging could be obtained at the Because of the high liver/spleen uptake which was found in the first two patients, a conventional colloid radionuclide scan was added to the protocol to assist interpretation of the antibody images. This was carried out 96h after injection of the antibody for these two patients, but within 24h before injection of the antibody in the remainder.
In order to ascertain the blood clearance rates of the radiolabelled antibody, 5ml blood samples were obtained at various times post-injection. These samples were centrifuged to separate red cells and plasma and the radioactivity in each component was assayed separately. The results were normalised for radioactive decay by counting a standard prepared from the dose residue with each sample.
Biokinetic data to enable dosimetric calculations to be carried out were obtained by drawing regions-of-interest around each of the major organs on the appropriate planar images and noting the total counts within each. This was carried out for both anterior and posterior views and the geometric mean of the two values for each organ calculated.
The mean was then multiplied by 1.8, a factor to take account of absorption in a 220mm thick body relative to a source in air, which was determined experimentally for indium-Ill. The data from each set of images were further normalised for radioactive decay and possible variations in gamma-camera sensitivity by imaging a standard each time the patient was imaged. radiolabelled monoclonal studies gave information not made available by normal computerised tomography, and in seven cases computerised tomography was superior. An analysis of these seven shows an equal distribution between situations in which the radiolabelled monoclonal failed to localise in clinically apparent disease sites and situations where apparent false positive localisation occurred. No patient showed any immediate or longer term adverse reaction to the injection of foreign protein.
The importance of good radiolabelling efficiency was demonstrated by the visualisation of renal activity, particularly in the 24 h scans, in patients where the labelling efficiency fell below approximately 95%. This may be attributed to free indium or indium colloid rather than to indium-DTPA, since the latter would have been excreted into urine. For therapy, this parameter will be of crucial importance.
The amount of protein administered might be thought to have a bearing on the uptake of the radiopharmaceutical. Table II shows the normalised counting rates obtained at 24h post-injection, excluding patients in whom any extravasation was noted. A total body count index was obtained by normalising the counts in the standard views obtained 24 h post-injection to a 100 s count time, summing the results and dividing by the amount of activity administered. It can be seen that there was no significant effect attributable to the variation in protein dose, even at the 200 pg level.
More than 95% of the activity remaining in the blood was associated with the plasma fraction from 1 h post-injection onwards. The blood clearance data can be fitted by a bi- exponential function, 62% of the activity having a half-time in blood of 9.6 h and the remaining 38% a half-time of 46.8h. Dosimetry was calculated according to the schema of the MIRD Committee. Organ uptake was assumed to occur instantaneously with the biodistribution of activity taken to be that found at 24 h post-injection. Other than the blood, biological half-life was taken as the physical half-life of the radionuclide. This will result in an overestimation of the dose, but the errors involved in the calculations do not justify more accurate quantification: there were substantial inter-patient differences in organ uptake. The resulting mean dose estimates are given in Table III. The radiation doses are generally higher than those extrapolated from animal data, particularly for the testes, due to the cross-reactivity discussed above. The figures are in general agreement with those given by Taylor et al. (1988) for a protein dose of 2.5mg of their antibody.
Discussion
These results are similar to previously published studies, suggesting that using similar monoclonal antibodies which recognised the high molecular weight antigen, approximately 80% of melanoma deposits can be detected. Siccardi et al. (1986) suggest that with small lesions of a diameter of 1 cm or less this detection rate may fall to only 59%. These authors also suggest that the lung is the most difficult area from which to obtain accurate images. This correlates with our own experience, and it may be that altered blood flow dynamics in and around pulmonary metastases result in poor perfusion of lung metastases and thus inadequate uptake. Cerny et al. (1987) suggest that particularly reliable images are obtained when studying metastatic deposits in bone, liver and lymph nodes, while lung, stomach and bowel are difficult areas for imaging. The latter two sites may give rise to problems with interpretation because of antibody excretion via the gastrointestinal tract. Kirkwood et al. (1987) comment that a very similar monoclonal antibody is cleared faster in males than in females or in one castrated male in their study, and also observe the apparently non-specific concentration of antibody in testicular tissue. This study also reports false positive results obtained in bone, heart, breast and thyroid.
It is possible that SPECT imaging of the thorax and abdomen routinely at 24h post-injection might contribute to further specificity and sensitivity of the imaging technique. Greater use of SPECT would also aid in the more precise localisation of soft tissue lesions. In particular, this might improve the diagnostic capability for lesions in lungs and liver. It should, however, be borne in mind that the individual reporting the images in this study had virtually no clinical information, whereas the CT scans were reported with full clinical details available. The accuracy of the imaging reports was noticeably improved in the latter patients.
An important observation in this study was that at protein doses of 1 mg and 200 gig, no detectable antimurine response was observed from serum samples taken 28 days postinjection. This important finding requires confirmation, but is encouraging in clinical situations where repeated use of foreign protein might be required. For example, this would allow imaging studies to be followed by therapeutic administration without accelerated clearance of the murine antibody. Patients 4 and 22 had tumour uptakes in the range 0.03-0.06% per gram, which would permit cell kill if the antibody were labelled with a beta-or alpha-emitting radionuclide. Strategies would be required to reduce the nontarget uptake of antibody, particularly that in liver and spleen. In view of the very poor response of metastatic melanoma to conventional chemotherapy, this approach to the management of advanced disease is clearly worthy of investigation and is in progress.
